BioSpace News Archive

Intuity Medical, Inc., the medical technology company committed to making it easier to live with diabetes, is announcing a partnership with HealthHavenRx™, an online pharmacy platform.

Macomics Ltd, a leader in macrophage drug discovery, has unveiled details of its lead programme, a first-in-class ligand independent-pan-LILRB monoclonal antibody for the treatment of cancer, having presented key data on MACO-355 at the American Association for Cancer Research Annual Meeting in San Diego1.

BrainStorm Cell Therapeutics Inc. announced that it received a notification letter on April 10, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market, indicating that the Company has regained compliance with the minimum market value of listed securities requirement set forth under Nasdaq Listing Rule 5550.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that it will host a live webcast on Thursday, April 25, 2024 at 8:00 a.m. ET to review first quarter 2024 financial results and discuss recent business updates.

Henry Schein, Inc. announced that it will release its first quarter 2024 financial results before the stock market opens on Tuesday, May 7, 2024, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m. Eastern time.

Sania Therapeutics, focused on developing targeted genetic medicines for prevalent disorders announces that it will be presenting three posters at the American Society of Gene & Cell Therapy 2024 Annual Meeting, taking place from 7-11 May 2024 in Baltimore, MD. Further details are below.

FundaMental Pharma GmbH, a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, is pleased to announce the appointment of Dr. Dirk Beher as Chief Executive Officer and Executive Board member.

Fortrea, a leading global contract research organization, announced that it will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system diseases, announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conference.

Nuevocor, a pre-clinical stage biotechnology company dedicated to developing novel medicines to treat cardiomyopathies with aberrant mechanobiology, announces the appointment of Dr. John Lee, MD, PhD, as its Chief Medical Officer.